MetaCap

Travere Therapeutics Inc. (TVTX)

NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

47.00-1.30 (-2.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TVTX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.67
52-week range
22.59 – 68.73
Day range
46.90 – 49.29
Volume / Avg
1.33M / 1.81M
Beta
—

52-week range

$22.59$68.73

TVTX stock today

On Nov 20, TVTX ended the session at $47.00, shedding $1.30 (2.69%), versus the S&P 500's 3.70% decline. At this level, TVTX sits in the middle of its 52-week range of $22.59 to $68.73: 31.6% below the high, set on Sep 11, 2026 and 108.1% above the low. TVTX is up 23.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 35.5%.

Travere Therapeutics has posted a net loss over the last twelve months (EPS of -$1.67), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Travere Therapeutics

Company profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Eric M. Dube Ph.D.
Headquarters
San Diego, CA
Employees
497

Financial highlights

Full financials

In fiscal 2025, Travere Therapeutics generated $490.7 million in revenue, up 110.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Travere Therapeutics reported a net loss of $25.5 million, compared with a loss of $321.5 million a year earlier. Gross margin was 97.9% (up from 96.7%) and operating margin -12.8%.

Travere Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$490.73M$233.18M$145.24M$109.46M$131.84M
Growth+110.45%+60.55%+32.69%-16.97%-33.52%
Net income$-25.55M$-321.55M$-111.40M$-278.48M$-180.09M
EPS (diluted)$-0.29$-4.08$-1.50$-4.37$-3.01

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$73.43+56.23%

  • Strong buy 2
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $62.00High $86.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$0.28 vs $-0.25
Surprise
+212.00%

TVTX news

All TVTX news

Travere Therapeutics peers

Health Care sector
TVTX peer companies
CompanyPrice% ChgMarket capCompare
IONSIonis Pharmaceuticals Inc.26.58-2.35%$4.43Bvs TVTX
COGTCogent Biosciences Inc.26.72-3.69%$4.65Bvs TVTX
EWTXEdgewise Therapeutics Inc.39.91-3.07%$4.37Bvs TVTX
PTCTPTC Therapeutics Inc.56.42-3.27%$4.71Bvs TVTX
DNTHDianthus Therapeutics Inc.84.55-0.33%$4.76Bvs TVTX
ERASErasca Inc.13.61-4.29%$4.78Bvs TVTX
LQDALiquidia Corporation54.43-3.88%$4.90Bvs TVTX
MANEVeradermics Incorporated119.52-3.92%$5.04Bvs TVTX

Indexes, lists and sector

Travere Therapeutics stock FAQ

What is Travere Therapeutics's stock price today?

TVTX last traded at $47.00 as of Nov 20, 4:00 PM EST, down 2.69% on the day. Prices are delayed at least 15 minutes.

Who is Travere Therapeutics's CEO?

Dr. Eric M. Dube Ph.D. is the chief executive officer of Travere Therapeutics Inc., which has about 497 employees.

What is the TVTX 52-week high?

The 52-week high for TVTX is $68.73 and the 52-week low is $22.59. The stock is currently 31.6% below its high.

Compare TVTX